All News
After failing a JAK inhibitor, can you still hit a JAK-pot?
Januse kinase (JAK) inhibitors are targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) that have risen in popularity as earlier treatment options for rheumatoid arthritis.
Read Article
ACR21 Best Abstracts - Day 2
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
Read Article
Daniela Ospina Cardona presenting at the Down and Dirty 30 on VEXAS. Marked differences in mortality depending on exact mutation. Looking forward to hearing more about this at Plenary session III today #ACR21 @RheumNow https://t.co/R3gXpxOfSk
Richard Conway RichardPAConway ( View Tweet)
Baricitinib for *relapsing* GCA (Th1+Th17)
w abbreviated steroid wean (15-22w)
Despite being tougher to treat:
100% off steroids at 24w
93% off steroids at 52w
no ischemic Sx
promising as another GCA Rx option!
(post-cessation 4pts flared)
@MayoClinic #ACR21 ABST1396 @RheumNow https://t.co/dqFnHQYogk
David Liew drdavidliew ( View Tweet)
It is #ACR21, but it is also #COP26Glasgow 🌎! What can we do for climate as physicians? "Our job is to make changes" Strong message for #ClimateAction from Dr Paul Dellaripa during his talk at the climate, pollution and IRMDs study group session @RheumNow https://t.co/GWxpzYD3lg
Aurelie Najm AurelieRheumo ( View Tweet)
"GCA is not a single, monolithic disease"
- Christian Dejaco, rightfully asking why we don't stratify treatment/trials in GCA
#ACR21 PMR/GCA Study Group @RheumNow @Sarah_L_Mackie @profbdasgupta @EBRheum @RichardPAConway @SattuiSEMD @drceowen
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow and its Faculty.
Dr. John Cush RheumNow ( View Tweet)
#ACR21 Abs#0819. RheumTAP real-world cohort of pts tapering Rx in remission on RA
▶️ Pts tapering 7.6x ⬆️ likely to flare in f/u
Great convo soon on @Rheumnow re: tapering studies. @davidliew asks how many more times do we need to see drug w/d fail?
https://t.co/BiZSM7yp7o https://t.co/iDXGVpFZzB
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 Rheum Pearls and Secrets
Not all (or most) ulcers is Behcet's! Here's a great approach to use in clinic. Jason Kolfenbach: "Sometimes, taking off the mask is worth it"
@Rheumnow https://t.co/OEBgf1eFhd
Eric Dein ericdeinmd ( View Tweet)
#ACR21. Powerful patient perspective by Amy Barron, RN and rheumatic patient
⭐️"I found hope advocating for arthritis" and found meaning in advocacy.
▶️ Consider talking to your patients about getting involved in ACR Advocacy to give purpose & community.
@ACRheumDC @CreakyJoints https://t.co/2mJRaShZQQ
Eric Dein ericdeinmd ( View Tweet)
Females axSpA pts presented w/ higher disease burden (fatigue/tiredness, & spinal pain at night.) Female axSpA pts achieved sign/symptom improvement with IXE later than male axSpA pts. Abs 0934 #ACR21 #RheumNow@RheumNow https://t.co/EGXnfeF6KQ https://t.co/TDF5zxtca7
Dr. Rachel Tate uptoTate ( View Tweet)
Oral Calcitonin not recommended for OA - studies did not show efficacy
Strontium Ranelate study below was considered a positive study in KOA with efficacy but had Cardiovascular toxicity - now off the market. https://t.co/gcYH9xoxeo
Bella Mehta bella_mehta ( View Tweet)
Wnt signaling - Lorecivivint is now in phase 3 https://t.co/JSk2nPBTrI
Bella Mehta bella_mehta ( View Tweet)
Abst 0789
Baker & colleagues examined adipokine levels in association with disease activity in RA patients
- Patients with high levels of adipokines less likely to achieve low disease activity & remission
- These patients more likely to escalate to b/tsDMARDs
#ACR21 @RheumNow https://t.co/1xlO4W9q9v
Akhil Sood MD AkhilSoodMD ( View Tweet)
Another exciting day at #ACR21 and covering for @RheumNow
Also presented my poster (Abstr 0587) DMARD Use in Medicare Patients with #RheumatoidArthritis and Risk of Long-Term Opioid Use
- DMARD users showed lower odds of long term opioid use compared to non-DMARD users https://t.co/2XZgYY8ORg
Akhil Sood MD AkhilSoodMD ( View Tweet)
Great time recapping D2 of ACR live with my fellow RheumNow Faculty! @RheumNow @drdavidliew @doctorRBC @DrMiniDey @swethaann23
Check it out here: https://t.co/4IcjkIlEb6
Be sure to keep tuning into https://t.co/nVnVgigOKL for more captivating coverage of #ACR21! https://t.co/Je6GxoBgiy
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
As old saying but updated goes: Wise man/woman/prefer not to answer says IF you STOP drugs they usually STOP working. True with TNFi in most diseases (RA, axSpA, etc). Also tue with #plaquenil in large #SLE study #ACR21 abst#0959 https://t.co/O6Ejg5sjjK
Janet Pope Janetbirdope ( View Tweet)
Recaps on highlights! This was fun!🤓
#ICYMI #ACR21 @RheumNow https://t.co/e7EjaDAzQ7
sheila RHEUMarampa ( View Tweet)
@RheumNow From Abst#3053 noted above, here we see the trend of urinary ALCAM with UPCr and renal-SLEDAI https://t.co/3Ujo8WTslO
Pedro Castillo _Castillo_Pedro ( View Tweet)
Stopping/reducing hydroxychloroquine (HCQ) in SLE associated with increased flares, especially for those in low disease activity or in remission. Super helpful data to share with pts wanting to reduce/dc HCQ.
#ACR21 Abst#0959 Plenary Session II @RheumNow https://t.co/i7jPDN2sgZ
Pedro Castillo _Castillo_Pedro ( View Tweet)